| Display title | Ibritumomab tiuxetan |
| Default sort key | Ibritumomab tiuxetan |
| Page length (in bytes) | 9,260 |
| Namespace ID | 0 |
| Page ID | 2742758 |
| Page content language | en - English |
| Page content model | wikitext |
| Indexing by robots | Allowed |
| Number of page watchers | Fewer than 30 watchers |
| Number of redirects to this page | 13 |
| Counted as a content page | Yes |
| Wikidata item ID | Q635415 |
| Local description | Radioimmunotherapy treatment |
| Central description | radioimmunotherapy treatment |
| Page image |  |
| Page views in the past 30 days | |
| Edit | Allow all users (no expiry set) |
| Move | Allow all users (no expiry set) |
| Page creator | 65.50.145.254 (talk) |
| Date of page creation | 03:13, 24 September 2005 |
| Latest editor | Boghog (talk | contribs) |
| Date of latest edit | 08:24, 28 July 2023 |
| Total number of edits | 161 |
| Recent number of edits (within past 30 days) | 0 |
| Recent number of distinct authors | 0 |
| Hidden categories (11) | This page is a member of 11 hidden categories (help):
|
| Transcluded templates (119) | Pages transcluded onto the current version of this page (help):
|
| Wikidata entities used in this page | - ibritumomab
- Sitelink
- Statement: P2566
- Statement: P628
- Statement: P3117
- Title
- Description: en
- Statement: P3493
|
